

HOTLINE: Effective November 16, 2020

**2009288 Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine PAIN HYB 2**

**Methodology:** Qualitative Liquid Chromatography-Tandem Mass Spectrometry/Enzyme Immunoassay/Quantitative Spectrophotometry

**Specimen Required:** Patient Prep: Information on the patient's current medications must be submitted with the order. Include trade name, generic name, dosing frequency and date of last dose, if known. Alternatively, please indicate if no prescription medication or drugs are being taken.  
Collect: Random urine.  
Specimen Preparation: Transfer 4 mL each into **two** (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each)  
Storage/Transport Temperature: Refrigerated  
Unacceptable Conditions: Specimens exposed to repeated freeze/thaw cycles.  
Stability (collection to initiation of testing): Ambient: 1 week (Clonazepam may be unstable at ambient condition beyond three days); Refrigerated: 1 month; Frozen: **1 month**

**Interpretive Data:**

Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available if ordered within two weeks of specimen collection. Additional charges apply.

For medical purposes only; not valid for forensic use.

**HOTLINE NOTE:** There is a clinically significant charting name change associated with this test.

Change the charting name for component 2007691, Pain Management Drug Panel from Pain Management Drug Panel to **Targeted drug profile panel**.

Change the charting name for component 2009289, EER Pain Mgt Pan, Mass Spec/EMIT Interp from EER Pain Mgt Pan, Mass Spec/EMIT Interp to **EER Tgt drug prof, MS/EMIT, UR, Interp**.

Change the charting name for component 2009291, Pain Management Drug Panel Interp from Pain Management Drug Panel Interp to **Targeted drug profile Interp**.